[Response to vaccination against the etiologic agent of viral hepatitis B (HBV) in a population at risk].
We report the results of the vaccinations against hepatitis B carried out with vaccine H-B-VAX of the commercial firm (Merck Sharp and Dohme), on 102 U.S.L. 32 hospital workers in Portomaggiore (Ferrara, Italy). The vaccine rendered 92% of the subjects inoculated immune and the incidence of secondary effects was low.